INTRODUCTION
Trastuzumab therapy initiated since august 2000 in 25% of the Metastatic Breast Cancer (MBC) patients over-expressing HER2. The product is licenced in monotherapy for patients pre-treated with anthracyclines and taxanes, or associated with paclitaxel for patients who can not be pre-treated by anthracyclines. Trastuzumab is an anti-HER2 monoclonal antibody immunotherapy. The French Ministry of health funded the HER.ME.S study started in 2001 to evaluate the economic impact of a targeted therapy.
METHODS

HER.ME.S (HERceptin/Métastatique/Sein) Study :
A clinical, biochemical and pharmaco-economic study : Prospective and multicentric trial. Clinical data were collated on line by 11 centers : 7 AP-HP (public assistance and hospitals of Paris) and 4 CRLCC (regional centers of fight against cancer).
Only HER2 3+ or 2+ and FISH+ patients received treatment Time to recruitment is 36 months, and in theory the follow-up time is 2 years The 2-months treatment response is evaluated according to RECIST criteria.
Pre-inclusion Biochemical Methods
• IHC (Immuno-HistoChemistry) test determinates the HER2 status.
• When HER2 status is 2+, HER2/neu amplification has to be evaluated by the FISH (Hybridation In Situ par Fluorescence) method.
• The H-ECD level is measured by ELISA (Enzyme Linked ImmunoSorban Assay) technique.
Statistical Methods
• Survival Analysis : Overall Survival, Time to Tumour Progression, Time to Treatment Failure, Progression Free Survival (Kaplan-Meier Method, log-rank test)
• ITT Analysis : TP1 versus TP3, test of comparison of means, Wilcoxon test and Khi-2 test.
• Correlations : Relative risk, McNemar test, Kappa Economic Analysis :
• Overall patient management cost includes pre-inclusion screening cost and treatment cost.
• Treatment cost was calculated by adding DRG costs (2004) and onerous drug reimbursed over DRGs.
• Drugs acquisition and biological and radiological examinations components were replaced by molecular real costs ( 
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OBJECTIVES
To evaluate the economic impact of trastuzumab treatment in MBC and to determinate the prediction level of the HER2 Extra-Cellular Domain (H-ECD) rate on the 2-months treatment response using correlations.
The 2-months response is compared to H-ECD level at baseline and after 2 months. Between -30% and +20% TP1
Between -100% and -30% T3 -100% T1 In a 3-years follow-up period, 120 patients were pre-included and 88 received trastuzumab treatment :
Treatment Schedule Designation
• Average age : 54 years .
• Median time to treatment: 30, .
patients dropped out :
• 
